Stay updated on Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page
- Check3 days agoChange DetectedAdded a Locations section with Illinois; removed the Illinois Locations listing and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedA new revision tag v3.3.2 was added and an earlier revision tag v3.2.0 was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedThe notice about government funding status was removed from the page, and this does not affect the trial details, eligibility criteria, or outcomes listed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check46 days agoChange DetectedUpdated the study status to Active, not recruiting with new milestone dates (e.g., 2025-11-05, 2026-03, 2025-11-03). Removed the PI note about cohorts closed for analysis and the suspended status along with several past dates (e.g., 2025-10-01, 2025-09, 2025-09-29).SummaryDifference0.4%

- Check53 days agoChange DetectedStudy status updated to Suspended Per PI with cohorts closed for analysis. Enrollment is affected and ongoing access to study information may be limited.SummaryDifference0.4%

- Check82 days agoChange DetectedUpdated operating-status notice and versioning: added a current funding/status banner and new date/revision (v3.2.0), while removing older date references and the previous revision (v3.1.0).SummaryDifference4%

Stay in the know with updates to Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page.